08:32 AM EDT, 08/18/2025 (MT Newswires) -- LakeShore Biopharma ( LSB ) shares were up nearly 8% in recent Monday premarket activity after the company said it had received a preliminary non-binding proposal letter from Oceanpine Capital to acquire the biopharmaceutical company in an all-cash deal.

The deal value of $0.86 per share represents a 10.3% premium to LakeShore's close on Friday.

LakeShore said that Oceanpine Capital plans to fund the deal using rollover equity and available cash on hand and that the deal is not subject to a financing condition.

LakeShore said its board "will carefully review and evaluate the proposal."